Lactoferrin and infections

What 2 graded rows on lactoferrin agree on for infections, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Lactoferrin page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Lactoferrin page, with its PubMed record.

Supplement

Lactoferrin Choose another

2 rows · 1,339 people

They agree: both rows found an improvement.

No difference

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside.

From the rows

The best-graded row, grade C, is a meta-analysis of 1,194 people (2021) and found an improvement.

The rows run from 145 to 1,194 people, published from 2021 to 2023: 1 pooled review and 1 single study.

2 improved

Grade CRespiratory tract infections · Improved
Meta-analysis, 6 studies · n 1,194 · 2021 · Participants in 6 randomized trials (9 eligible)
Varied across trials · Varied across trials
Odds of a respiratory infection were 43% lower than control (odds ratio 0.57); two trials were at high risk of bias.
Row on the Lactoferrin page · PubMed 34620326 (opens PubMed)
Grade CRespiratory and whole-body symptom scores in healthy adults · Improved
RCT · n 145 · 2023 · Healthy adults at a Japanese university
200 mg/day · 12 weeks
Total respiratory and systemic symptom scores were lower than with placebo, and plasmacytoid dendritic cell activation markers were higher at week 12; adverse events did not differ.
Row on the Lactoferrin page · PubMed 37764743 (opens PubMed)